个性化治疗的承诺
几位演讲者在UEG 2015covered the theme of personalizing risk prediction and treatment for gastrointestinal diseases. During a press conference,迈克尔·法尔highlighted the importance of understanding diseases at the molecular level, which may allow treatment at an almost individual extent. The immediate benefits are significant savings in time and expenses, and also decreased chances of administering the wrong drugs.
预防结直肠癌（CRC）对于减轻这种毁灭性疾病的负担至关重要一个ntoni Castells讨论了改善个性化风险预测在CRC预防中。
全基因组和全基因组范围的关联研究（GWAS和EWAS）是通过非侵入性手术使患者风险分层的宝贵工具。如有必要，应在阳性基因测试后处于阳性基因检测后的患者进行筛查。
林奇综合征患者的外显子组测序allows the identification of mutations in cancer predisposition genes, which are not necessarily expected according to patients’ history. Selecting the patients who can benefit the most from colonoscopy screening can increase likelihood of better CRC prevention and patient adherence.
个性化医学是关于在分子水平上了解疾病，几乎在患者范围内治疗。
迈克尔·法尔
幽门螺杆菌和胃癌
胃癌目前是激烈研究的重点，因为它们在全球的存在是由多种因素引起的。H. Pylorigerms are present in全球人口的三分之二，，，，and their infections are main drivers of gastric disease, which in turn can develop into cancers.
In their最近发表的论文，，，，理查德·亨特（Richard Hunt）同事回顾了健康胃的重要性以及如何H. Pylorican severely disrupt gastric physiology, concluding that disease prevention and public awareness are fundamental to reduce gastric diseases.
也在Sugano及其同事的论文，，，，results from the Kyoto Global Consensus meeting reveal the importance of treatingH. Pyloriinfection before atrophic gastritis development, stressing that eradication ofH. Pylorireduces the risk of gastric cancer.
病毒和自身免疫性肝病
鉴于其复杂的病毒学和异构治疗选择。在ECC 2015，，，，海纳·韦德梅耶（Heiner Wedemeyer）报道了许多用于丙型肝炎治疗的药物是目前正在发布，在2016年有更多的预期。
当组合施用时，这些药物针对三种分子类型（-asvirs，-previrs和buvirs）来治疗丙型肝炎。需要更大的研究以证明有关此类治疗安全的同类研究的最新积极数据，这可能允许允许AHCV相关肝脏死亡的急剧下降在未来几十年。
多亏了许多GWAS研究，我们现在开始了解驱动大量自身免疫性肝病的因素。一个最近的研究by Farh and colleagues identified the shared genetic features between different autoimmune diseases, which will eventually allow to manage each specific disease in a targeted way.
Finally, primary biliary cirrhosis was recently renamed原发性胆管炎，认识到胆管炎是炎症状态，而不是肝病的终结状态。这一重要变化将影响正在接受治疗的临床医生和患者。
Non-alcoholic fatty liver disease (NAFLD) – new therapeutic hopes
一个talk by阿伦·萨尼亚（Arun Sanyal）provided an overview of the current therapeutic advances in nonalcoholic steatohepatitis (NASH) treatment, the most common form of chronic liver disease. About a third of the general population presents a fatty liver, but a lower proportion will then progress towards steatohepatitis and cirrhosis.
Paul Angulo及其同事在他们的纵向研究纤维化阶段与长期相关联ortality and serious adverse events, unlike any other histologic features of steatohepatitis. This can allow risk-stratification of patients with confirmed NAFLD according to their risk profile, using non-invasive techniques to reduce unnecessary cost and choose the most appropriate targeted therapy. Surgery can then be considered for more advanced cases.
Obeticholic酸是一种源自天然胆汁酸的分子，在其中报告的初始结果由弗林特试验表明这可能是提高纳什组织学特征的有前途的药物。但是，它的长期收益和安全需要额外的研究。
一个s highlighted byRui Eduardo Castroin the talk onNASH from bench to bedside，，，，several factors contribute to the advance of NAFLD. The disease can eventually develop into hepatocellular carcinoma (HCC), where almost 40% of risk factors are related to diabetes and obesity.
肝硬化不一定是向HCC发展的先决条件，但是核受体和miRNA在NAFLD进步的多种致病机制中涵盖了重要作用。我们期待发布研究疾病发展原因的试验。
BMC医学：对质量，透明和临床影响充满热情
2014年中位数流动时间：初始决定三天；同行评审后的决定41天
Comments